We intend to focus our search in the technology, media and telecommunications industries and on companies with sustainability business models (“TMTS”) that are enabled by technology. (Note: CIIG Capital Partners II, Inc., upsized its SPAC IPO at pricing on Sept. 14, 2021, to 25 million units, up from 22.5 million units in the prospectus, at […]

This is a new blank-check company or SPAC formed by XP, an investment firm in Brazil. (This new SPAC is incorporated in the Cayman Islands.) We intend to capitalize on the strength and leading presence of the XP platform in Brazil, drawing upon the extensive networks, relationships and investment acumen of our sponsor and management […]

We intend to focus our search on software companies, especially those targeting enterprise vertical sectors owned by private equity and venture capital firms as well as corporate carve-outs. Our management team has had significant success sourcing, acquiring, growing and monetizing these types of companies. We believe this experience makes us well suited to identify, source, […]

We intend to focus our search on green-economy-focused metals and mining businesses in high quality, stable jurisdictions that would benefit from access to the deep and highly-liquid U.S. public markets along with the additional capital that may be secured through those markets to unlock value. (Incorporated in the Cayman Islands)  (Note: Metals Acquisition Corp. priced […]

We intend to pursue targets in North America, Europe and Asia (excluding China) in the media and entertainment industry. We shall not undertake our initial business combination with any entity with its principal business operations in China (including Hong Kong and Macau). (New blank-check company or SPAC incorporated in Delaware) We intend to focus specifically […]

We are a preclinical biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, the leading cause of death in the world, and in doing so improve and extend the lives of […]

(Note: This is NOT a traditional IPO. IPOScoop has NO CALL on this offering because it is a NASDAQ uplisting from the AIM, which is operated by the London Stock Exchange. The last reported sale price of our common stock on July 23, 2021, was 10 British pounds sterling per share, or about US$13.79 per […]

We are a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation.  By prioritizing target selectivity, we believe our drug candidates have the potential to […]

Note: Immuneering Corp. is a preclinical biopharma company. From the prospectus: “We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a […]

We intend to focus our initial business combination search in the ecommerce sector, specifically on companies offering Software-as-a-Service (“SaaS”) products and services to enterprise customers globally. We currently intend to focus on opportunities that capitalize on the expertise and ability of our management team, particularly our Chairman, M. Blair Garrou; our President and Chief Executive […]